The Case for Holding MetLife Stock: What Investors Need to Know

MetLife shares are down 11.7% year-to-date but the article highlights valuation support, with MET trading at a 6.9x forward P/E vs. 8.3x for the industry. Zacks expects 2026 EPS of $9.85 (+11.6% YoY) on 2026 revenue of $77.7B, and notes the stock has beaten estimates in 2 of the last 4 quarters (avg EPS surprise ~0.12%). Business tailwinds include 2025 premium growth of 10.8% and margin improvement via the New Frontier 2025 plan (net direct expense ratio down to 11.7%), alongside strong liquidity (~$22B cash vs. $14.5B long-term debt) and $2.1B remaining under repurchase authorization.

Analysis

MET screens cheap, but insurance multiples usually stay compressed when the market doubts the durability of asset-yield support. The core question is not the forward P/E; it is whether management can turn buybacks and cost cuts into higher ROIC, because low capital efficiency tends to cap rerating even when earnings are growing.

The better near-term setup is not absolute upside in MET, but relative rotation within financials. If investors keep rewarding estimate momentum and earnings-beat consistency, capital should favor names with cleaner underwriting / pricing power and less dependence on volatile investment income. That makes MET vulnerable to being a funding source for higher-quality peers rather than a destination for new money.

Tail risk is on the asset side: private equity/real estate marks and reinvestment yields can overwhelm operating progress if markets wobble. Over the next 1-3 months, the key catalyst is whether earnings revisions turn from mixed to positive after the next print; over 6-18 months, the thesis is falsified if ROIC moves sustainably toward or above the group average and buybacks materially lift per-share growth. If that does not happen, the current discount is more likely a value trap than a rerating setup.

Key Decisions for Investors

• Watchlist, not a conviction long: buy MET only on post-earnings weakness if the stock is >6.5x forward earnings and management reaffirms 2026 investment income guidance; target a 10-15% rebound, stop if the next print shows another investment-income miss.
• Relative-value pair: long ALL / short MET over the next 1-3 months. The bet is that the market pays up for cleaner earnings momentum and underweights MET's lower ROIC; risk/reward improves if MET outperforms by >5% on a guide-up or capital-return surprise.
• If you want direct exposure to a valuation rerate, prefer HCI or MCY over MET on a 3-6 month horizon. The setup is better estimate momentum, so MET’s discount can remain cheap while the higher-conviction names get the multiple expansion.
• Set an alert on MET's investment income trend and credit/CRE marks into the next earnings cycle. Any downward revision to investment income or capital return would be a near-term falsifier and likely trigger another de-rating.